Deferred Tax Assets, Valuation Allowance of Aclaris Therapeutics, Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Aclaris Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Aclaris Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $197,111,000, a 12% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Aclaris Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $197,111,000 -$27,249,000 -12% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $224,360,000 +$29,236,000 +15% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $195,124,000 +$10,436,000 +5.7% 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q4 2022 $184,688,000 +$22,864,000 +14% 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q4 2021 $161,824,000 +$27,265,000 +20% 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q4 2020 $134,559,000 +$13,593,000 +11% 31 Dec 2020 10-K 27 Feb 2024 2023 FY
Q4 2019 $120,966,000 +$39,981,000 +49% 31 Dec 2019 10-K 23 Feb 2023 2022 FY
Q4 2018 $80,985,000 +$34,107,000 +73% 31 Dec 2018 10-K 24 Feb 2022 2021 FY
Q4 2017 $46,878,000 +$16,152,000 +53% 31 Dec 2017 10-K 25 Feb 2021 2020 FY
Q4 2016 $30,726,000 +$17,440,000 +131% 31 Dec 2016 10-K 25 Feb 2020 2019 FY
Q4 2015 $13,286,000 +$6,842,000 +106% 31 Dec 2015 10-K 18 Mar 2019 2018 FY
Q4 2014 $6,444,000 +$3,545,000 +122% 31 Dec 2014 10-K 12 Mar 2018 2017 FY
Q4 2013 $2,899,000 +$2,209,000 +320% 31 Dec 2013 10-K 15 Mar 2017 2016 FY
Q4 2012 $690,000 31 Dec 2012 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.